🇺🇸 FDA
Pipeline program

Mavorixafor

X4P-001-104

Phase 3 small_molecule active

Quick answer

Mavorixafor for Neutropenia is a Phase 3 program (small_molecule) at X4 Pharmaceuticals, Inc with 2 ClinicalTrials.gov record(s).

Program details

Company
X4 Pharmaceuticals, Inc
Indication
Neutropenia
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials